Bariatric Surgery vs GLP-1 Therapy in a Patient With Class II Obesity and Knee Osteoarthritis
A 44-year-old man with BMI 38.1 kg/m² (weight 118 kg, height 1.76 m), hypertension (on lisinopril 20 mg), and bilateral knee osteoarthritis limiting walking to 10 minutes per day presents for weight management. He has tried two structured lifestyle programs without sustained loss. He is interested in 'whatever works fastest' and asks about both bariatric surgery and injectable medications. Labs: A1c 5.9%, LDL 110 mg/dL, eGFR 88, no history of pancreatitis, no personal or family history of medullary thyroid carcinoma or MEN2. He has a physically demanding job and cannot afford prolonged time off.
1. Compare the anticipated outcomes and burdens of sleeve gastrectomy versus semaglutide 2.4 mg for this patient, and identify which factors should drive the decision.
Read the worked answer
Sleeve gastrectomy. Expected total weight loss ~25–30% at 1–2 years, with durable improvements in hypertension, osteoarthritis pain, and progression to diabetes. Burdens: perioperative risk, 2–4 weeks of restricted activity, lifelong micronutrient monitoring, reflux risk, and irreversible anatomy. He meets standard eligibility (BMI ≥35 with comorbidity).
Semaglutide 2.4 mg. Expected ~15% weight loss at 68 weeks; requires chronic use, titration, GI side effects, cost, and does not produce the same magnitude of loss. Reversible. No contraindications identified here.
Decision drivers.
- Magnitude needed: BMI 38 with functional limitation - surgery offers greater and more durable loss, which matters for knee loading.
- Time off work: surgery conflicts with his stated constraint; a GLP-1 trial does not.
- Durability and adherence: surgery is one-time but requires lifelong follow-up; GLP-1 requires sustained access and adherence.
- Reversibility preference: if he values reversibility, start with pharmacotherapy.
Judgment. A reasonable approach is a time-limited GLP-1 trial (e.g., 6 months) with a pre-set response threshold (e.g., ≥10% loss), while simultaneously completing bariatric evaluation so surgery remains an option if the trial fails or is not tolerated. Do not let his 'fastest' framing override the occupational constraint.
2. He asks whether starting a GLP-1 receptor agonist now would 'ruin' his chances of surgery later. How do you respond, and what would you monitor during a GLP-1 trial?
Read the worked answer
Response. Preoperative GLP-1 use does not preclude surgery and is increasingly used as a bridge. However, it changes the preoperative picture: loss may reduce BMI below insurance thresholds (a practical access issue, not a medical one), and there are anesthesia considerations regarding gastric emptying and aspiration risk that require holding the drug per current perioperative guidance before elective surgery.
Monitoring during the trial.
- Weight and waist circumference monthly; define a response threshold in advance.
- A1c and blood pressure at 3 and 6 months.
- GI tolerability and hydration; assess for gallbladder symptoms with rapid loss.
- Functional outcome (walking time, pain) as a patient-centered endpoint.
- Reassess whether surgery evaluation should proceed in parallel.
Key judgment. Frame GLP-1 therapy as complementary to, not competing with, surgical evaluation, and address the access/threshold issue explicitly rather than letting it emerge as a surprise.